News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
24,383 Results
Type
Article (1020)
Company Profile (2)
Press Release (23361)
Section
Business (12775)
Career Advice (64)
Deals (1590)
Drug Development (2178)
Employer Resources (1)
FDA (360)
Job Trends (611)
News (16171)
Policy (632)
Tag
Academia (16)
Alliances (778)
ALS (12)
Alzheimer's disease (11)
Antibody-drug conjugate (ADC) (3)
Approvals (378)
Artificial intelligence (4)
Autoimmune disease (1)
Bankruptcy (4)
Best Places to Work (510)
Biotechnology (2)
Bladder cancer (8)
Brain cancer (1)
Breast cancer (5)
Cancer (104)
Cardiovascular disease (5)
Career advice (58)
CAR-T (3)
Cell therapy (13)
Clinical research (1927)
Collaboration (29)
Compensation (13)
Complete response letters (1)
COVID-19 (34)
CRISPR (3)
C-suite (3)
Data (130)
Depression (2)
Diabetes (9)
Diagnostics (228)
Digital health (1)
Drug discovery (1)
Drug pricing (1)
Duchenne muscular dystrophy (2)
Earnings (12361)
Employer resources (1)
Events (1841)
Executive appointments (3)
FDA (508)
Frontotemporal dementia (1)
Funding (11)
Gene editing (3)
Gene therapy (5)
GLP-1 (17)
Government (60)
Guidances (115)
Healthcare (596)
IgA nephropathy (2)
Immunology and inflammation (4)
Indications (3)
Infectious disease (36)
Inflammatory bowel disease (4)
Influenza (1)
Intellectual property (5)
Interviews (19)
IPO (1161)
Job creations (124)
Job search strategy (35)
Labor market (1)
Layoffs (6)
Legal (118)
Longevity (1)
Lung cancer (24)
Lymphoma (22)
Manufacturing (3)
MASH (6)
Medical device (572)
Medtech (575)
Mergers & acquisitions (443)
Metabolic disorders (27)
Multiple sclerosis (7)
NASH (1)
Neurodegenerative disease (2)
Neuropsychiatric disorders (4)
Neuroscience (41)
NextGen: Class of 2025 (108)
Non-profit (44)
Obesity (11)
Opinion (4)
Ovarian cancer (3)
Parkinson's disease (4)
Partnered (2)
Patents (11)
Patient recruitment (1)
People (564)
Phase I (436)
Phase II (704)
Phase III (856)
Pipeline (389)
Postmarket research (121)
Preclinical (211)
Prostate cancer (7)
Radiopharmaceuticals (5)
Rare diseases (3)
Real estate (100)
Recruiting (1)
Regulatory (513)
Reports (3)
Research institute (33)
Resumes & cover letters (11)
RNA editing (1)
Schizophrenia (5)
Series A (1)
Sickle cell disease (2)
Special edition (1)
Spinal muscular atrophy (3)
Startups (39)
Supply chain (1)
Tariffs (2)
Vaccines (10)
Venture capital (1)
Weight loss (6)
Women's health (2)
Date
Today (3)
Last 7 days (12)
Last 30 days (37)
Last 365 days (1414)
2025 (989)
2024 (1683)
2023 (1862)
2022 (2023)
2021 (1981)
2020 (1731)
2019 (1125)
2018 (917)
2017 (701)
2016 (410)
2015 (711)
2014 (462)
2013 (265)
2012 (335)
2011 (417)
2010 (409)
Location
Africa (15)
Alabama (1)
Arizona (7)
Asia (1328)
Australia (163)
California (375)
Canada (103)
China (15)
Colorado (27)
Connecticut (8)
Delaware (15)
Europe (2671)
Florida (65)
Georgia (15)
Idaho (4)
Illinois (27)
Indiana (23)
Japan (3)
Kansas (4)
Kentucky (2)
Louisiana (6)
Maine (8)
Maryland (54)
Massachusetts (250)
Michigan (16)
Minnesota (29)
Mississippi (1)
Missouri (2)
Montana (1)
Nevada (5)
New Hampshire (4)
New Jersey (127)
New York (89)
North Carolina (44)
Northern California (201)
Ohio (14)
Pennsylvania (108)
South America (36)
Southern California (138)
Tennessee (6)
Texas (42)
United States (1413)
Utah (19)
Virginia (4)
Washington State (39)
West Virginia (1)
Wisconsin (4)
24,383 Results for "119".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Cell and Gene Therapy Market Size Expected to Hit USD 119.30 Billion by 2034
September 18, 2025
·
1 min read
Press Releases
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
August 19, 2025
·
1 min read
Press Releases
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
June 30, 2025
·
6 min read
Press Releases
Proenkephalin A 119-159 (penKid) Leads the Way in Predicting Graft Outcomes for Kidney Transplant Recipients
July 1, 2025
·
3 min read
Press Releases
Noom Launches Microdose GLP-1 Program, Enabling Weight Loss Without the Side Effects and Priced at $119 to Start, Including Medication and Microhabits Program
August 5, 2025
·
8 min read
Press Releases
Generic Sterile Injectable Market Size to Reach USD 119.65 Bn by 2034 High Demand for Low-cost Treatments and Chronic Disease Prevalence
July 7, 2025
·
1 min read
Pharm Country
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
Aprea Therapeutics, Inc. today announced that the Safety Review Committee (SRC) overseeing the ongoing ABOYA-119 clinical trial has determined that dosing of patients with ATRN-119 at 800 mg once daily (Cohort 6) can commence and that Cohort 6 is open for enrollment.
May 28, 2024
·
7 min read
Press Releases
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%
May 8, 2025
·
19 min read
Press Releases
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
December 11, 2024
·
7 min read
Policy
Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
Vivani Medical, Inc. announced the U.S. Food and Drug Administration has cleared the Investigational New Drug Application and lifted the clinical hold on NPM-119 to allow initiation of LIBERATE-1™, a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of NPM-119, the Company’s miniature, six-month GLP-1 implant in development for the treatment of type 2 diabetes.
June 13, 2024
·
7 min read
1 of 2,439
Next
